細胞治療的共同研究及授權契約:2016年～2025年

"細胞療法合作與許可交易" 報告提供了前所未有的途徑，讓我們能夠全面了解全球領先生物製藥公司簽署的細胞療法交易。

本報告詳細介紹了2016年至2025年的細胞療法交易，並詳細分析了企業達成細胞療法交易的方式和原因。這些交易通常包含多個環節，從合作研發到成果商業化。

本報告涵蓋合作、開發、研究和授權交易，並包含自2016年以來宣布的989項細胞療法交易的完整清單。此外，報告還包含本公司及其合作夥伴向美國證券交易委員會提交的合約文件（如有）。

本報告的第一章介紹了細胞療法交易。

第一章是對報告的介紹。

第2章概述了自2016年以來的細胞療法交易活動。

第3章概述了自2016年以來的主要細胞療法交易。交易按總價值列出。

第4章列出了在細胞療法交易中最活躍的25家公司，隨後進行了簡要總結，並提供了完整的細胞療法交易清單和公開的合約文件。

第5章全面深入地回顧了自2016年1月以來已完成和宣布的細胞療法交易，重點介紹了已公開合約文件的交易。

第6章全面深入地回顧了自2016年1月以來已完成和宣布的細胞療法合作計畫。本章按感興趣的特定細胞療法技術類型進行組織。

該報告還包含大量圖表和數據，展現了自2016年以來細胞療法交易活動和趨勢。

此外，綜合交易目錄依公司A-Z、交易類型及治療目標進行整理。每個交易標題都透過網頁連結連結到線上交易記錄，並在可用的地方包含合約文件，方便您隨時存取每份協議文件。

主要的優點

"細胞療法合作與授權協議" 一書提供讀者以下主要優勢：

• 了解自2016年以來的交易趨勢
• 瀏覽細胞療法合作與許可交易
• 基準分析 - 確定交易的市場價值
• 財務條款 - 一次性付款、里程碑付款、特許權使用費
• 依公司A-Z、交易類型及治療領域排序的交易目錄
• 依交易價值排序的主要交易
• 最活躍的交易撮合者
• 確定每筆交易的資產和交易條款
• 存取合約文件 - 深入了解交易結構
• 盡職調查 - 評估擬議交易條款是否適合您的合作公司
• 節省數百小時的研究時間

研究範圍

• 細胞療法 "合作與許可交易" 旨在深入了解全球領先生物製藥公司達成的細胞療法趨勢和交易結構。

細胞療法合作與許可交易包括：

• 生物製藥產業的細胞療法交易趨勢
• 涵蓋製藥和生物技術領域的細胞療法交易記錄目錄
• 主要細胞療法交易
• 最活躍的細胞療法許可交易撮合者
• "細胞療法合作與許可交易" 提供全面的交易記錄存取權限，包括合約文件。

分析合約文件有助於進行以下方面的盡職調查：

• 授予或選擇的具體權利是什麼？
• 實際授予合約夥伴什麼？
• 授予了哪些獨家權利？
• 合約的付款結構是怎樣的？
• 銷售和付款如何審計？
• 合約期限是多久？
• 合約的關鍵條款如何界定？
• 知識產權如何處理歸屬於誰？
• 誰負責商業化？
• 誰負責開發、供應和製造？
• 如何管理保密和資訊揭露？
• 如何解決爭議？
• 合約在什麼情況下可以終止？
• 如果所有權發生變更會怎樣？
• 雙方約定了哪些分授權和分包條款？
• 公司堅持哪些標準條款？
• 哪些標準條款在不同合作夥伴或不同交易類型之間似乎有所不同？
• 公司在契約法方面主張哪些管轄權？

目錄

摘要整理

第1章 簡介

第2章 細胞治療交易趨勢

• 簡介
• 多年的細胞治療交易
• 最活躍的細胞治療交易業者
• 細胞治療交易，各交易類型
• 細胞治療交易，各治療領域
• 細胞治療交易，各業界
• 細胞治療交易的交易條件
  • 細胞治療交易的主要金額
  • 細胞治療契約的預付款金
  • 細胞治療契約的里程金
  • 細胞治療的特許權率

第3章 -主要細胞治療交易

• 簡介
• 主要的細胞治療交易，各金額

第4章 -最活躍的細胞治療交易業者

• 簡介
• 最活躍的細胞治療交易業者
• 最活躍的細胞治療交易的企業簡介

第5章 細胞治療契約交易名錄

• 簡介
• 細胞治療契約交易名錄

第6章 各技術類型的細胞治療交易

• 交易名錄
• 交易名錄- 細胞治療交易(AZ)，公司
• 交易名錄- 細胞治療交易，各交易類型
• 交易名錄- 細胞治療交易，各治療領域
• 交易類型定義
• 關於調查公司
• 目前共同研究
• 目前契約
• 最近的報告標題

Cell Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cell therapy deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of cell therapy deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter cell therapy deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 989 cell therapy deals announced since 2016 including financial terms where available including links to online deal records of actual cell therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of cell therapy dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in cell therapy dealmaking since 2016.

Chapter 3 provides an overview of the leading cell therapy deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in cell therapy dealmaking with a brief summary followed by a comprehensive listing of cell therapy deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of cell therapy deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of cell therapy partnering deals signed and announced since Jan 2016. The chapter is organized by specific cell therapy technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in cell therapy deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Cell Therapy Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse cell therapy collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Cell Therapy Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cell therapy trends and structure of deals entered into by leading biopharma companies worldwide.

Cell Therapy Collaboration and Licensing Deals includes:

• Trends in cell therapy dealmaking in the biopharma industry
• Directory of cell therapy deal records covering pharmaceutical and biotechnology
• The leading cell therapy deals by value
• Most active cell therapy licensing dealmakers
• Cell Therapy Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cell therapy dealmaking

• 2.1. Introduction
• 2.2. Cell therapy deals over the years
• 2.3. Most active cell therapy dealmakers
• 2.4. Cell therapy deals by deal type
• 2.5. Cell therapy deals by therapy area
• 2.6. Cell therapy deals by industry sector
• 2.7. Deal terms for cell therapy deals
  • 2.7.1 Cell therapy deals headline values
  • 2.7.2 Cell therapy deal upfront payments
  • 2.7.3 Cell therapy deal milestone payments
  • 2.7.4 Cell therapy royalty rates

Chapter 3 - Leading cell therapy deals

• 3.1. Introduction
• 3.2. Top cell therapy deals by value

Chapter 4 - Most active cell therapy dealmakers

• 4.1. Introduction
• 4.2. Most active cell therapy dealmakers
• 4.3. Most active cell therapy deals company profiles

Chapter 5 - Cell therapy contracts dealmaking directory

• 5.1. Introduction
• 5.2. Cell therapy contracts dealmaking directory

Chapter 6 - Cell therapy dealmaking by technology type

• Deal directory
• Deal directory - Cell therapy deals by company A-Z
• Deal directory - Cell therapy deals by deal type
• Deal directory - Cell therapy deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Cell therapy deals since 2016
• Figure 2: Active cell therapy dealmaking activity - 2016 - 2025
• Figure 3: Cell therapy deals by deal type since 2016
• Figure 4: Cell therapy deals by therapy area since 2016
• Figure 5: Cell therapy deals by industry sector since 2016
• Figure 6: Cell therapy deals with a headline value
• Figure 7: Cell therapy deals with an upfront value
• Figure 8: Cell therapy deals with a milestone value
• Figure 9: Cell therapy deals with a royalty rate value
• Figure 10: Top cell therapy deals by value since 2016
• Figure 11: Most active cell therapy dealmakers 2016 - 2025
• Figure 12: Cell therapy deals by technology type since 2016